Context: Compassionate deactivation (CD) of ventricular assist device (VAD) support is a recognized option for children when the burden of therapy outweighs the benefits.
Objectives: To describe the prevalence, indications, and outcomes of CD of children supported by VADs at the end of life.
Methods: Review of cases of CD at our institution between 2011 and 2020. To distinguish CD from other situations where VAD support is discontinued, patients were excluded from the study if they died during resuscitation (including extracorporeal membrane oxygenation), experienced brain or circulatory death prior to deactivation, or experienced a non-survivable brain injury likely to result in imminent death regardless of VAD status.
Results: Of 24 deaths on VAD, 14 (58%) were CD. Median age was 5.7 (interquartile range (IQR) 0.6, 11.6) years; 6 (43%) had congenital heart disease; 4 (29%) were on a device that can be used outside of the hospital. CD occurred after 40 (IQR: 26, 75) days of support; none while active transplant candidates. CD discussions were initiated by the caregiver in 6 (43%) cases, with the remainder initiated by a medical provider. Reasons for CD were multifactorial, including end-organ injury, infection, and stroke. CD occurred with endotracheal extubation and/or discontinuation of inotropes in 12 (86%) cases, and death occurred within 10 (IQR: 4, 23) minutes of CD.
Conclusion: CD is the mode of death in more than half of our VAD non-survivors and is pursued for reasons primarily related to noncardiac events. Caregivers and providers both initiate CD discussions. Ventilatory and inotropic support is often withdrawn at time of CD with ensuing death.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpainsymman.2021.01.125 | DOI Listing |
ASAIO J
November 2021
The Department of Medical Ethics, The Children's Hospital of Philadelphia.
J Pain Symptom Manage
September 2021
Department of Anesthesia, Stanford University School of Medicine (D.C.), Palo Alto, California, USA.
Context: Compassionate deactivation (CD) of ventricular assist device (VAD) support is a recognized option for children when the burden of therapy outweighs the benefits.
Objectives: To describe the prevalence, indications, and outcomes of CD of children supported by VADs at the end of life.
Methods: Review of cases of CD at our institution between 2011 and 2020.
Curr Heart Fail Rep
August 2020
Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Purpose Of Review: Although the utilization of mechanical circulatory support (MCS) devices is increasing, ethical dilemmas regarding device deactivation and dying process persist, potentially complicating delivery of optimal and compassionate care at end-of-life (EOL). This review aims to study EOL challenges, left ventricular assist devices (LVADs) as a nuanced life support treatment, legal history in the US impacting EOL care, and suggestions to improve EOL care for patients on MCS support.
Recent Findings: Recent studies have demonstrated challenging aspects of EOL care for patients on LVAD support: low use of advanced directives, high rates of surrogate decision-making due to lack of patient capacity, difficult decision-making involving LVAD deactivation even with cooperating patients, and high rates of death in the hospital and ICU settings.
Pediatr Transplant
November 2019
Congenital Heart Center, Department of Pediatrics, University of Florida, Gainesville, FL, USA.
Single-ventricle pediatric patients, amongst other children waiting for OHT, are a vulnerable population, especially if candidacy is established before any palliation. NH is a rare disease with poor prognosis in the post-natal period. We present a case of sub-acute NH diagnosed in an infant with HLHS who was listed for OHT while bridged with a pulsatile paracorporeal VAD, with an emphasis on the evolution of the condition throughout the patient's clinical course and the ultimate decision for compassionate deactivation of VAD.
View Article and Find Full Text PDFPediatr Transplant
May 2019
Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts.
Objectives: This study's objective was to investigate compassionate ventricular assist device deactivation (VADdeact) in children from the perspective of the pediatric heart failure provider.
Background: Pediatric VAD use is a standard therapy for advanced heart failure. Serious adverse events may affect relative benefit of continued support, leading to consideration of VADdeact.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!